Skip to main content
. Author manuscript; available in PMC: 2024 Feb 18.
Published in final edited form as: Pharmacol Biochem Behav. 2023 Feb 18;223:173530. doi: 10.1016/j.pbb.2023.173530

Table 2,

cAMP signalling potencies and efficacies of ligands investigated in HEK cells expressing 5HT1a/CB1, or 5HT1a-alone and CB1-alone

Drug condition Cell line pEC50 ± SEM Emax (% inhib of Fsk), ± SEM n
8OH-DPAT 5HT1a/CB1 8.39 ± 0.21 66.6 ± 1.3 5
5HT1a 8.54 ± 0.03 71.5 ± 3.6 3
AMB-FUBINACA 5HT1a/CB1 9.21 ± 0.14 61.0 ± 1.7 4
CB1 9.56 ± 0.09 60.8 ± 1.7 3
pFPP 5HT1a/CB1 ~5.20 ± 0.18$ ND 3
5HT1a ~4.83 ± 0.13$ ND 3
AMB-FUBINACA + pFPP (31.6 μM) 5HT1a/CB1 9.39 ± 0.11 64.9 ± 3.5 3
CB1 9.70 ± 0.16 57.9 ± 2.33 3
AMB-FUBINACA + WAY100635 (1 μM) 5HT1a/CB1 9.11 ± 0.16 59.4 ± 9.17 3
CB1 9.65 ± 0.14 55.7 ± 5.78 3
$

Emax of pFPP concentration-response curves were not fully defined due to low potency. To allow approximation of potency values, curves were constrained to the maximum effect produced by 8OH-DPAT in each cell line.